<

ABSCIENCES (EPA:AB) AB Science announced today that it has received authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001)

Transparency directive : regulatory news

16/09/2021 19:34



Other stories

24/04/2024 21:51
24/04/2024 21:02
24/04/2024 19:41
24/04/2024 23:00
24/04/2024 18:33
25/04/2024 00:58
24/04/2024 20:02
24/04/2024 13:22
24/04/2024 19:00
24/04/2024 17:42
24/04/2024 21:37
25/04/2024 00:03
25/04/2024 00:05
24/04/2024 22:03
24/04/2024 21:05
24/04/2024 21:32
24/04/2024 18:04
24/04/2024 12:05
24/04/2024 20:41
24/04/2024 18:09
24/04/2024 17:37
23/04/2024 15:30
18/04/2024 10:48
24/04/2024 21:52
24/04/2024 21:39
24/04/2024 18:28
25/04/2024 00:11
25/04/2024 00:18
24/04/2024 23:18
25/04/2024 01:57
24/04/2024 07:30
24/04/2024 17:00
24/04/2024 08:05
23/04/2024 12:10
24/04/2024 20:53
24/04/2024 09:15
23/04/2024 20:17
25/04/2024 00:39